Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China

被引:2
|
作者
Zhang, Yingfang [1 ,2 ]
Liu, Lei [3 ]
Duan, Xinwang [4 ]
Pi, Hui [5 ]
Jiang, Lili [5 ]
Li, Jiang [6 ]
Wang, Guochun [1 ,2 ,7 ,8 ]
Shu, Xiaoming [1 ,2 ,7 ,8 ]
机构
[1] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Rheumatol, Key Lab Myositis, Beijing, Peoples R China
[3] Zhejiang Univ, Dept Rheumatol, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 2, Dept Rheumatol & Immunol, Nanchang, Jiangxi, Peoples R China
[5] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Dept Rheumatol, Nanchang, Peoples R China
[6] China Japan Friendship Hosp, Dept Lab Med, Beijing, Peoples R China
[7] China Japan Friendship Hosp, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China
[8] China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
anti-SAE antibody; DM; skin rash; cancer; interstitial lung disease; outcome; MODIFIER ACTIVATING ENZYME; IDIOPATHIC INFLAMMATORY MYOPATHIES; MYOSITIS-SPECIFIC AUTOANTIBODIES; CLINICAL-SIGNIFICANCE; JAPANESE PATIENTS; CANCER; ADULT; CLASSIFICATION; IDENTIFICATION; POLYMYOSITIS;
D O I
10.1093/rheumatology/keae232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe the longitudinal study and long-term prognosis of a multicentre large inception cohort of patients with anti-SAE positive DM.Methods We retrospectively recruited patients with anti-SAE+DM in four tertiary referral centres from China between March 2005 and December 2022. Long-term survival analysis was performed on the enrolled patients. The Myositis Damage Index and Cutaneous Disease Area and Severity Index were used to evaluate the degree of different organ damage and the extent of skin rashes. Longitudinal CT patterns were analysed. Phenotypes were characterized using unsupervised cluster analysis.Results All-cause death occurred in 10.5% (4/38) of all patients, in which three patients succumbed to malignancies at 13, 18 and 36 months. Most patients had favourable long-term outcomes, 35.3% of them were in drug-free remission. Skin rashes showed significant improvement evaluated by Cutaneous Disease Area and Severity Index with time. However, damage to different systems was observed in 70.6% of the surviving patients using the Myositis Damage Index, which mainly consisted of skin damage, accounting for 47.1%. Nine patients with anti-SAE+DM-associated interstitial lung disease underwent repeat CT showed marked radiological improvement at 6 months or being stable after 12 months. In further, different characteristics and outcomes were also showed in three clusters identified by unsupervised analysis.Conclusions Anti-SAE+DM is characterized with a lower mortality rate and the development of malignancies being the primary cause of death. Patients who survived showed notable cutaneous damage, while the interstitial lung disease tends to stabilize. Clusters identified with unsupervised analysis could assist physicians in identifying a higher risk of mortality.
引用
收藏
页码:1377 / 1385
页数:9
相关论文
共 50 条
  • [41] Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis
    Nakanishi, Yu
    Yamaguchi, Kakuhiro
    Yoshida, Yusuke
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Miyamoto, Shintarou
    Iwamoto, Hiroshi
    Hirata, Shintaro
    Fujitaka, Kazunori
    Hamada, Hironobu
    Sugiyama, Eiji
    Hattori, Noboru
    INTERNAL MEDICINE, 2020, 59 (20) : 2553 - 2558
  • [42] Anti-p155/140 Antibody-positive Dermatomyositis with Metastases Originating from an Unknown Site
    Ohashi, Masafumi
    Shu, En
    Tokuzumi, Masataka
    Fujioka, Kei
    Ishizuka, Tatsuo
    Hara, Akira
    Fujimoto, Manabu
    Kaji, Kenzo
    Seishima, Mariko
    ACTA DERMATO-VENEREOLOGICA, 2011, 91 (01) : 84 - 85
  • [43] Characteristics of anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis with thrombotic microangiopathy
    Ushijima, Toshiyuki Shiki
    Komai, Toshihiko
    Izuka, Shinji
    Shoda, Hirofumi
    Fujio, Keishi
    MODERN RHEUMATOLOGY, 2024, 34 (05) : 973 - 977
  • [44] Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease-a case report
    Kishi, Takayuki
    Tani, Yumi
    Okiyama, Naoko
    Mizuochi, Kiyoshi
    Ichimura, Yuki
    Harigai, Masayoshi
    Nagata, Satoru
    Miyamae, Takako
    PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)
  • [45] Anti-PL-7 antibody-positive dermatomyositis with progressive interstitial pneumonia complicated with tracheal ulcer
    Sato, Shintaro
    Yamakawa, Hideaki
    Takemura, Tamiko
    Nakamura, Tomohiko
    Oba, Tomohiro
    Nishizawa, Tomotaka
    Kawabe, Rie
    Akasaka, Keiichi
    Amano, Masako
    Matsushima, Hidekazu
    RESPIRATORY MEDICINE CASE REPORTS, 2021, 33
  • [46] The risk of cancer in patients with connective tissue diseases but without dermatomyoSitis or polymyositis: A multicenter cohort study conducted over 15 years in China
    Xu, Wei
    Guo, Huan
    Liu, Zhi
    Chen, Chen
    Lei, Cong-Cong
    IMMUNOLOGY LETTERS, 2016, 177 : 70 - 74
  • [47] External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China
    Chen, Bi
    Xi, Bin
    Xin, Hongxia
    Zou, Ruyi
    Tian, Yaqiong
    Zhao, Qi
    Yan, Xin
    Qiu, Xiaohua
    Gao, Yujuan
    Liu, Yin
    Cao, Min
    Jiang, Hanyi
    He, Ping
    Chen, Juan
    Cai, Hourong
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2025, 72
  • [48] Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis
    Kurasawa, Kazuhiro
    Arai, Satoko
    Namiki, Yumeko
    Tanaka, Ayae
    Takamura, Yuta
    Owada, Takayoshi
    Arima, Masafumi
    Maezawa, Reika
    RHEUMATOLOGY, 2018, 57 (12) : 2114 - 2119
  • [49] A case of anti-Mi-2 antibody-positive dermatomyositis associated with malignant lymphoma
    Ohashi, Masafumi
    Takagi, Hajime
    Hayakawa, Masaya
    Hamaguchi, Yasuhito
    Seishima, Mariko
    MODERN RHEUMATOLOGY CASE REPORTS, 2019, 3 (01) : 62 - 66
  • [50] Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review
    Xie, Huaiya
    Zhang, Dingding
    Wang, Yuanzhuo
    Shi, Yixin
    Yuan, Yuan
    Wang, Luo
    Fan, Junping
    Tian, Xinlun
    Wang, Jinglan
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 62